Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
Blood
|
August 14, 2013
PARP-1 regulates expression of TGF-β receptors in T cells
Pin Zhang, Hiroko Nakatsukasa, Eric Tu, et al.
Nature Immunology
|
September 1, 2015
The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells
Hiroko Nakatsukasa, Dunfang Zhang, Takashi Maruyama, et al.
JCI Insight
|
February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Eric Tu, Kelly McGlinchey, Jixin Wang, et al.
Journal for Immunotherapy of Cancer
|
November 17, 2024
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Diwakar Davar, Benedito A Carneiro, Grace K Dy, et al.
Cancer Research Communications
|
September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors
John Powderly, Martina Imbimbo, Antoine Italiano, et al.
The Journal of Clinical Investigation
|
November 15, 2023
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Journal of Personality and Social Psychology
|
October 31, 2024
A worldwide test of the predictive validity of ideal partner preference matching
Paul W Eastwick, Jehan Sparks, Eli J Finkel, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
Blood
|
August 14, 2013
PARP-1 regulates expression of TGF-β receptors in T cells
Pin Zhang, Hiroko Nakatsukasa, Eric Tu, et al.
Nature Immunology
|
September 1, 2015
The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells
Hiroko Nakatsukasa, Dunfang Zhang, Takashi Maruyama, et al.
JCI Insight
|
February 8, 2022
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Eric Tu, Kelly McGlinchey, Jixin Wang, et al.
Journal for Immunotherapy of Cancer
|
November 17, 2024
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Diwakar Davar, Benedito A Carneiro, Grace K Dy, et al.
Cancer Research Communications
|
September 3, 2025
IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors
John Powderly, Martina Imbimbo, Antoine Italiano, et al.
The Journal of Clinical Investigation
|
November 15, 2023
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, et al.
Journal of Personality and Social Psychology
|
October 31, 2024
A worldwide test of the predictive validity of ideal partner preference matching
Paul W Eastwick, Jehan Sparks, Eli J Finkel, et al.
Page
of 3